We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Pennsylvania district court refused to certify a group of corporate and institutional drug purchasers as plaintiffs in a class-action antitrust suit against several drugmakers — saying the approximately two-dozen organizations in the class was relatively small and did not meet legal class-action requirements. Read More
Sens. Elizabeth Warren (D-Mass.) and Shelley Moore Capito (R-W.Va.) urged FDA Commissioner Scott Gottlieb to task the agency’s opioid policy steering committee with promoting “partial fill” policies to limit the number of unused pills in circulation. Read More
If Congress were to require a Medicaid-style rebate structure for Medicare Part B prescription drugs, drugmakers would have to pay at least $1.8 billion in annual rebates — about 9 percent of Medicare’s total spending on pharmaceuticals in 2015 — according to an HHS analysis. Read More
Insys Therapeutics should be prosecuted for efforts to increase use of its fentanyl spray Subsys, according to Sen. Claire McCaskill (D-Mo.), in a report from her investigation into opioid manufacturers and distributors. Read More
Two AIDS patient advocacy groups urged New York Attorney General Eric Schneiderman — a frequent foe of anticompetitive behavior by drugmakers — to investigate potential pay-for-delay deals by Gilead. Read More
Arizona joined the growing number of states filing lawsuits alleging marketing fraud by opioid manufacturers, as Attorney General Mark Brnovich filed suit against Insys Therapeutics and three doctors for allegedly being part of a fraudulent and misleading marketing effort for Susys (fentanyl). Read More
Baxter International will divest the rights to two drugs held by Claris Lifesciences to offset the anticompetitive effects of its acquisition of Claris, under terms of a final FTC order. Read More
A Pennsylvania district court refused to certify a group of corporate and institutional drug purchasers as plaintiffs in a class-action antitrust suit against several drugmakers — saying the approximately two-dozen organizations in the class was relatively small and did not meet legal class-action requirements. Read More